CRIP1 expression is correlated with a favorable outcome and less metastases in osteosarcoma patients

Predicting the clinical course of osteosarcoma patients is a crucial prerequisite for a better treatment stratification in these highly aggressive neoplasms of bone. In search of new and reliable biomarkers we recently identified cysteine-rich intestinal protein 1 (CRIP1) to have significant prognostic impact in gastric cancer and therefore decided to investigate its role also in osteosarcoma. For this purpose we analyzed 223 pretherapeutic and well characterized osteosarcoma samples for their immunohistochemical expression of CRIP1 and correlated our findings with clinico-pathological parameters including follow-up, systemic spread and response to chemotherapy. Interestingly and contrarily to gastric cancer, we found CRIP1 expression more frequently in patients with long-term survival (10-year survival 73% in positive vs. 54% in negative cases, p = 0.0433) and without metastases (p = 0.0108) indicating a favorable prognostic effect. CRIP1 therefore seems to represent a promising new biomarker in osteosarcoma patients which should be considered for a prospective validation.

[1]  S. Rauser,et al.  MALDI imaging identifies prognostic seven-protein signature of novel tissue markers in intestinal-type gastric cancer. , 2011, The American journal of pathology.

[2]  M. Rosemann,et al.  Genomic Alterations and Allelic Imbalances Are Strong Prognostic Predictors in Osteosarcoma , 2010, Clinical Cancer Research.

[3]  J. Ramser,et al.  Identification of brain- and bone-specific breast cancer metastasis genes. , 2009, Cancer letters.

[4]  G. Kristiansen,et al.  Expression of CD24, P-cadherin and S100A4 in tumors of the ampulla of Vater , 2009, Modern Pathology.

[5]  Q Wang,et al.  Hypomethylation of WNT5A, CRIP1 and S100P in prostate cancer , 2007, Oncogene.

[6]  R. Steele,et al.  Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer , 2006, Journal of Clinical Pathology.

[7]  Stefan Roepcke,et al.  Transcriptional census of 36 microdissected colorectal cancers yields a gene signature to distinguish UICC II and III , 2006, International journal of cancer.

[8]  Yi Zhang,et al.  Genes associated with breast cancer metastatic to bone. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Erming Tian,et al.  Gene expression profiles of primary HPV16- and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapy. , 2005, Virology.

[10]  A. Stromberg,et al.  Thiamine transporter gene expression and exogenous thiamine modulate the expression of genes involved in drug and prostaglandin metabolism in breast cancer cells. , 2004, Molecular cancer research : MCR.

[11]  Allison Jones,et al.  cDNA microarray analysis of genes associated with ERBB2 (HER2/neu) overexpression in human mammary luminal epithelial cells , 2003, Oncogene.

[12]  R. Salunga,et al.  Gene expression profiles of human breast cancer progression , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[13]  David Yang,et al.  Identification of cervical cancer markers by cDNA and tissue microarrays. , 2003, Cancer research.

[14]  L. Lanningham-Foster,et al.  Overexpression of CRIP in transgenic mice alters cytokine patterns and the immune response. , 2002, American journal of physiology. Endocrinology and metabolism.

[15]  Tatjana Crnogorac-Jurcevic,et al.  Characterization of gene expression profiles in intraductal papillary-mucinous tumors of the pancreas. , 2002, The American journal of pathology.

[16]  L. Lanningham-Foster,et al.  Regulation of cysteine-rich intestinal protein, a zinc finger protein, by mediators of the immune response. , 2000, The Journal of infectious diseases.

[17]  J. Gordon,et al.  Developmental regulation of a gene that encodes a cysteine-rich intestinal protein and maps near the murine immunoglobulin heavy chain locus. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[18]  P. Komminoth,et al.  Pathology and Genetics of Tumours of Soft Tissue and Bone , 2013 .

[19]  Colin Kong,et al.  Biomarkers in Osteosarcoma. , 2009, Expert opinion on medical diagnostics.

[20]  G. Delling,et al.  Morphological grades of regression in osteosarcoma after polychemotherapy — Study COSS 80 , 2004, Journal of Cancer Research and Clinical Oncology.

[21]  W. Winkelmann,et al.  Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  F. Mertens,et al.  World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone , 2002 .